BR0207068A - Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus - Google Patents
Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureusInfo
- Publication number
- BR0207068A BR0207068A BR0207068-5A BR0207068A BR0207068A BR 0207068 A BR0207068 A BR 0207068A BR 0207068 A BR0207068 A BR 0207068A BR 0207068 A BR0207068 A BR 0207068A
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- isolated
- infection
- clfa protein
- aureus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
"ANTICORPO MONOCLONAL PARA A PROTEìNA ClfA, ANTI-SORO ISOLADO, ANTICORPO ISOLADO E ANTICORPO HUMANIZADO CONTENDO O REFERIDO ANTICORPO, KIT DIAGNóSTICO COMPREENDENDO O REFERIDO ANTICORPO, MéTODO PARA DIAGNóSTICO DE UMA INFECçãO POR S.aureus, COMPOSIçãO FARMACêUTICA PARA O TRATAMENTO OU PREVENçãO DA REFERIDA INFECçãO, MéTODO PARA INDUçãO DE DE UMA RESPOSTA IMUNOLóGICA, MéTODO PARA IDENTIFICAçãO DE ANTICORPOS MONOCLONAIS PARA A PROTEìNA ClfA E FRAGMENTO ATIVO ISOLADO A PARTIR DO DOMìNIO A DA PROTEìNA ClfA DO S.aureus". São apresentados anticorpos monoclonais que podem se ligar a uma proteína ClfA e que são gerados a partir de sub-domínios de ligação ou fragmentos ativos da proteína ClfA do Staphylococcus aureus, incluindo as proteínas de fragmentos ativos de seu domínio de ligação fibrinogênica tais como a proteína Clf40, a proteína Clf33, ou ClfA N3, que podem ser úteis no tratamento e proteção contra infecções por bactérias estafilocócicas tais como Staphylococcus aureus. Além disso, instrumentos médicos podem ser tratados utilizando os anticorpos monoclonais da presente invenção com o objetivo de reduzir ou eliminar a possibilidade de que estes sejam infectados ou de uma proliferação adicional da infecção. Em particular, os anticorpos da presente invenção são vantajosos porque podem impedir a aderência da bactéria às células hospedeiras através do comprometimento ou inibição da capacidade da S. aureus ClfA de se ligar ao fibrinogeno ou fibrina, e assim podem ser utilizados em métodos ou tratamento ou prevenção de infecções estafilocócicas.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26407201P | 2001-01-26 | 2001-01-26 | |
| US27461101P | 2001-03-12 | 2001-03-12 | |
| US29841301P | 2001-06-18 | 2001-06-18 | |
| US30811601P | 2001-07-30 | 2001-07-30 | |
| PCT/US2002/002296 WO2002072600A2 (en) | 2001-01-26 | 2002-01-28 | Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0207068A true BR0207068A (pt) | 2004-12-21 |
Family
ID=27500806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0207068-5A BR0207068A (pt) | 2001-01-26 | 2002-01-28 | Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6979446B2 (pt) |
| EP (1) | EP1377314B1 (pt) |
| JP (1) | JP4171816B2 (pt) |
| KR (2) | KR20030071861A (pt) |
| CN (2) | CN101928343B (pt) |
| AT (1) | ATE524195T1 (pt) |
| AU (1) | AU2002256985B8 (pt) |
| BR (1) | BR0207068A (pt) |
| CA (1) | CA2434762A1 (pt) |
| DK (1) | DK1377314T3 (pt) |
| ES (1) | ES2372686T3 (pt) |
| IL (2) | IL157041A0 (pt) |
| MX (1) | MXPA03006651A (pt) |
| PT (1) | PT1377314E (pt) |
| WO (1) | WO2002072600A2 (pt) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6994855B1 (en) * | 1994-08-22 | 2006-02-07 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
| US6692739B1 (en) * | 1998-08-31 | 2004-02-17 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| HUE026914T2 (en) * | 2002-11-07 | 2016-08-29 | Immunogen Inc | Anti-CD33 antibodies and a method of treating acute myeloid leukemia |
| US7425328B2 (en) * | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
| WO2006138627A2 (en) * | 2005-06-16 | 2006-12-28 | Inhibitex, Inc. | Monoclonal antibodies recognizing a coagulase-negative staphylococcal protein |
| US20110091480A1 (en) * | 2006-01-27 | 2011-04-21 | Brown Martha J | Antigen-Binding Proteins Targeting S. Aureus Orf0657n |
| WO2007100580A2 (en) * | 2006-02-22 | 2007-09-07 | The Texas A & M University System | Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use |
| WO2008136861A2 (en) * | 2006-11-22 | 2008-11-13 | 3M Innovative Properties Company | Inactivated and dried biological preparations |
| JP2010510524A (ja) | 2006-11-22 | 2010-04-02 | スリーエム イノベイティブ プロパティズ カンパニー | 試料を調製及び分析するシステム並びに方法 |
| US20100129837A1 (en) * | 2006-11-22 | 2010-05-27 | Mach Patrick A | Methods of capturing bacterial whole cells and methods of analyzing samples for bacteria |
| EP2140264A1 (en) * | 2007-04-19 | 2010-01-06 | 3M Innovative Properties Company | Methods of use of solid support material for binding biomolecules |
| US20100209946A1 (en) * | 2007-04-19 | 2010-08-19 | Naiyong Jing | Uses of water-dispersible silica nanoparticles for attaching biomolecules |
| WO2009029132A2 (en) * | 2007-05-31 | 2009-03-05 | Merck & Co., Inc. | Antigen-binding proteins targeting s. aureus orf0657n |
| JP2011504236A (ja) * | 2007-11-20 | 2011-02-03 | スリーエム イノベイティブ プロパティズ カンパニー | ジアセチレンを含むポリマーセンサーを用いる細菌試料の分析方法 |
| EP2250503A2 (en) * | 2008-02-20 | 2010-11-17 | 3M Innovative Properties Company | Methods of analyzing samples for bacteria using whole cell capture and atp analysis |
| MX2012000044A (es) | 2009-06-22 | 2012-01-30 | Wyeth Llc | Composiciones inmunogenicas de antigenos de staphylococcus aureus. |
| EP2454284B1 (en) | 2009-07-15 | 2018-04-11 | AIMM Therapeutics B.V. | Gram-positive bacteria specific binding compounds |
| AU2010291835A1 (en) * | 2009-09-03 | 2012-04-19 | Vancouver Biotech Ltd. | Monoclonal antibodies against gonadotropin-releasing hormone receptor |
| EA201792376A3 (ru) | 2009-10-23 | 2018-08-31 | Милленниум Фармасьютикалз, Инк. | Молекулы анти-gcc антитела и соответствующие композиции и способы |
| AU2010328359B2 (en) * | 2009-12-07 | 2015-02-05 | Decimmune Therapeutics, Inc. | Anti-inflammatory antibodies and uses therefor |
| DK3252076T3 (da) | 2011-01-14 | 2019-12-02 | Univ California | Diagnostisk anvendelse af antistoffer mod ror-1-protein |
| KR101044438B1 (ko) * | 2011-03-29 | 2011-06-27 | 최희선 | 저수탱크 |
| WO2013012743A2 (en) * | 2011-07-15 | 2013-01-24 | The University Of Chicago | Methods and compositions for inhibiting staphylococcus agglutination in blood |
| CN103857697A (zh) * | 2011-09-23 | 2014-06-11 | 伍兹堡尤利乌斯－马克西米利安斯大学 | 形成金黄色葡萄球菌表位结合位点的肽或肽的组合 |
| US8834898B2 (en) * | 2011-12-16 | 2014-09-16 | Boise State University | Cholera toxin chimera and its use as a staph vaccine |
| US9988439B2 (en) | 2011-12-23 | 2018-06-05 | Nicholas B. Lydon | Immunoglobulins and variants directed against pathogenic microbes |
| EP2793944A4 (en) * | 2011-12-23 | 2015-09-02 | Nicholas B Lydon | IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES |
| ES2749181T3 (es) | 2012-04-27 | 2020-03-19 | Millennium Pharm Inc | Moléculas de anticuerpo anti-GCC y uso de las mismas para ensayar la susceptibilidad a una terapia dirigida a GCC |
| EP2705852A1 (en) * | 2012-09-06 | 2014-03-12 | Université de Lausanne | An immunogenic composition against Staphylococcus aureus comprising an inactivated recombinant non-pathogenic bacterium |
| JP6694269B2 (ja) * | 2012-11-06 | 2020-05-13 | メディミューン，エルエルシー | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体 |
| US9409977B2 (en) | 2013-03-12 | 2016-08-09 | Decimmune Therapeutics, Inc. | Humanized, anti-N2 antibodies |
| JP6554099B2 (ja) | 2013-08-07 | 2019-07-31 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | ｐ５３変異体を再活性化することの可能なペプチド |
| JP2017502002A (ja) | 2013-12-09 | 2017-01-19 | ニューヨーク・ユニバーシティ | 抗ブドウ球菌剤の食細胞送達用組成物及び方法 |
| US11446371B2 (en) * | 2015-11-05 | 2022-09-20 | The Texas A&M University System | Targeting of ligand binding sites in ClfA |
| CA3012302A1 (en) | 2016-02-04 | 2017-08-10 | Yeda Research And Development Co. Ltd. | Peptides and use of same in the treatment of diseases, disorders or conditions associated with a mutant p53 |
| AU2017266288A1 (en) | 2016-05-18 | 2019-01-03 | Genmab B.V. | Antibodies and methods of use thereof in treatment of infectious disease |
| US11155608B2 (en) * | 2017-08-23 | 2021-10-26 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against pathological alpha-synuclein, and methods using same |
| KR20210008408A (ko) * | 2018-05-23 | 2021-01-21 | 싱가포르국립대학교 | T-세포 악성 종양의 면역요법을 위한 cd2 표면 발현 및 키메라 항원 수용체의 발현에 대한 차단 |
| CN110632298B (zh) * | 2018-06-25 | 2023-04-18 | 洛阳普泰生物技术有限公司 | 犬腺病毒1型单克隆抗体、可变区序列、杂交瘤细胞株及其应用 |
| WO2020023644A2 (en) * | 2018-07-24 | 2020-01-30 | Medimmune, Llc | Antibody directed against s. aureus clumping factor a (clfa) |
| AU2019357983A1 (en) | 2018-10-09 | 2021-05-27 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
| JP2022519631A (ja) | 2019-02-12 | 2022-03-24 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法 |
| US20220298255A1 (en) * | 2019-05-31 | 2022-09-22 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | E-cadherin activating antibodies and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK219084D0 (da) | 1984-05-02 | 1984-05-02 | Frederik Carl Peter Lindberg | Antigen |
| US5240833A (en) * | 1989-01-30 | 1993-08-31 | The Biomembrane Institute | Method for the production of monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides |
| CA2072249C (en) * | 1991-06-28 | 2003-06-17 | Saiko Hosokawa | Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane |
| US5256542A (en) * | 1992-03-09 | 1993-10-26 | Tanox Biosystems, Inc. | Selecting low frequency antigen-specific single B lymphocytes with correction for background noise |
| ZA936260B (en) * | 1992-09-09 | 1994-03-18 | Smithkline Beecham Corp | Novel antibodies for conferring passive immunity against infection by a pathogen in man |
| GB9223377D0 (en) * | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| CA2153661A1 (en) | 1993-01-12 | 1994-07-21 | Anthony George Gristina | Methods and compositions for the direct concentrated delivery of passive immunity |
| DE69535374T2 (de) * | 1994-02-09 | 2007-08-23 | Epitopix Llc, Willmar | Aktive immunisierung gegen ein siderophores rezeptorprotein |
| US5648240A (en) | 1994-05-24 | 1997-07-15 | Texas A&M University | MHC II analog from Staphylococcus aureus |
| US6008341A (en) | 1994-08-22 | 1999-12-28 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
| EP0781847A1 (en) * | 1995-11-06 | 1997-07-02 | MERCK PATENT GmbH | Humanized monoclonal antibody |
| ATE309271T1 (de) | 1996-05-16 | 2005-11-15 | Texas A & M Univ Sys | Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen |
| SE9704141D0 (sv) | 1997-11-12 | 1997-11-12 | Sbl Vaccin Ab | New protein and nucleotide sequence, encoding said protein |
| JP2002523474A (ja) | 1998-08-31 | 2002-07-30 | インヒビテツクス，インコーポレイテツド | ドナーの選択およびドナーの刺激によるブドウ球菌の免疫療法 |
| EP1125130B1 (de) | 1998-10-29 | 2006-07-26 | DakoCytomation Denmark A/S | Nachweis von säure-resistenten mikroorganismen im stuhl |
| AU4810600A (en) * | 1999-04-28 | 2000-11-10 | Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin, The | Method of inhibiting leukocyte adhesion to fibrinogen |
-
2002
- 2002-01-28 ES ES02726561T patent/ES2372686T3/es not_active Expired - Lifetime
- 2002-01-28 KR KR10-2003-7009897A patent/KR20030071861A/ko active Search and Examination
- 2002-01-28 KR KR1020097006616A patent/KR101015496B1/ko active IP Right Grant
- 2002-01-28 CN CN200910250224.7A patent/CN101928343B/zh not_active Expired - Fee Related
- 2002-01-28 DK DK02726561.0T patent/DK1377314T3/da active
- 2002-01-28 CA CA002434762A patent/CA2434762A1/en not_active Abandoned
- 2002-01-28 WO PCT/US2002/002296 patent/WO2002072600A2/en active Application Filing
- 2002-01-28 JP JP2002571513A patent/JP4171816B2/ja not_active Expired - Fee Related
- 2002-01-28 US US10/056,052 patent/US6979446B2/en not_active Expired - Lifetime
- 2002-01-28 AU AU2002256985A patent/AU2002256985B8/en not_active Ceased
- 2002-01-28 CN CNA028042220A patent/CN1489474A/zh active Pending
- 2002-01-28 EP EP02726561A patent/EP1377314B1/en not_active Expired - Lifetime
- 2002-01-28 IL IL15704102A patent/IL157041A0/xx unknown
- 2002-01-28 AT AT02726561T patent/ATE524195T1/de active
- 2002-01-28 MX MXPA03006651A patent/MXPA03006651A/es active IP Right Grant
- 2002-01-28 BR BR0207068-5A patent/BR0207068A/pt not_active Application Discontinuation
- 2002-01-28 PT PT02726561T patent/PT1377314E/pt unknown
-
2003
- 2003-07-21 IL IL157041A patent/IL157041A/en not_active IP Right Cessation
-
2005
- 2005-05-25 US US11/136,559 patent/US7364738B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20050287164A1 (en) | 2005-12-29 |
| CN1489474A (zh) | 2004-04-14 |
| ATE524195T1 (de) | 2011-09-15 |
| AU2002256985B8 (en) | 2008-03-20 |
| KR101015496B1 (ko) | 2011-02-22 |
| MXPA03006651A (es) | 2004-11-12 |
| US7364738B2 (en) | 2008-04-29 |
| PT1377314E (pt) | 2012-01-02 |
| JP4171816B2 (ja) | 2008-10-29 |
| CA2434762A1 (en) | 2002-09-19 |
| CN101928343B (zh) | 2014-09-17 |
| EP1377314A4 (en) | 2005-05-11 |
| EP1377314B1 (en) | 2011-09-14 |
| WO2002072600A2 (en) | 2002-09-19 |
| ES2372686T3 (es) | 2012-01-25 |
| US20030099656A1 (en) | 2003-05-29 |
| KR20090039851A (ko) | 2009-04-22 |
| WO2002072600A3 (en) | 2003-11-06 |
| JP2004534000A (ja) | 2004-11-11 |
| IL157041A0 (en) | 2004-02-08 |
| AU2002256985B2 (en) | 2007-10-11 |
| EP1377314A2 (en) | 2004-01-07 |
| US6979446B2 (en) | 2005-12-27 |
| CN101928343A (zh) | 2010-12-29 |
| DK1377314T3 (da) | 2011-12-12 |
| KR20030071861A (ko) | 2003-09-06 |
| IL157041A (en) | 2010-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0207068A (pt) | Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus | |
| Sugimoto et al. | Staphylococcus epidermidis Esp degrades specific proteins associated with Staphylococcus aureus biofilm formation and host-pathogen interaction | |
| Prabhakara et al. | Murine immune response to a chronic Staphylococcus aureus biofilm infection | |
| Würzner et al. | Inhibition of terminal complement complex formation and cell lysis by monoclonal antibodies | |
| AU2002305450A1 (en) | Proteomimetic compounds and methods | |
| DE69940404D1 (de) | Multikomponenten Impfstoffe gegen Staphylococcus aureus | |
| Siqueira et al. | Leptospira interrogans Lsa23 protein recruits plasminogen, factor H and C4BP from normal human serum and mediates C3b and C4b degradation | |
| BR0011000A (pt) | Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico | |
| WO2005056600A3 (en) | Monoclonal antibodies that bind or neutralize dengue virus | |
| CY1113182T1 (el) | Συνθεσεις και μεθοδοι για την αντιμετωπιση ιογενους λοιμωξης | |
| EA201001212A1 (ru) | Лечение микробных инфекций | |
| DK1636561T3 (da) | Kombinatorisk proteinbiblioteksscreening ved hjælp af periplasmatisk ekspression | |
| BRPI0413495A (pt) | reagentes de peptìdeos especìficos para prìons e seus usos | |
| AR016295A1 (es) | Antigeno de superficies y proteinas utiles de composiciones para el diagnostico y prevencion de la enfermedad de lyme | |
| ATE310088T1 (de) | Behandlung und nachweis von staphylokokkeninfektionen | |
| Martini et al. | Type IV pili of Streptococcus sanguinis contribute to pathogenesis in experimental infective endocarditis | |
| Nelson et al. | Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma | |
| Tkaczyk et al. | Neutralizing Staphylococcus aureus virulence with AZD6389, a three mAb combination, accelerates closure of a diabetic polymicrobial wound | |
| Harro et al. | Clearance of Staphylococcus aureus from in vivo models of chronic infection by immunization requires both planktonic and biofilm antigens | |
| RU2015143696A (ru) | МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА ПРОТИВ АНТИТРОМБИНА β | |
| WO2022011110A3 (en) | Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection | |
| WO2022150654A3 (en) | Antigen-binding polypeptides specific for coronaviruses and uses thereof | |
| Frye et al. | A soft tick Ornithodoros moubata salivary protein OmCI is a potent inhibitor to prevent avian complement activation | |
| BR112022026575A2 (pt) | Anticorpos de alta afinidade que alvejam tau fosforilado em serina 413 | |
| WO2002020619A3 (en) | HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |